| 19 | 1/1 | 返回列表 |
| 查看: 471 | 回復(fù): 18 | |||
| 【有獎(jiǎng)交流】積極回復(fù)本帖子,參與交流,就有機(jī)會(huì)分得作者 wtxlcy 的 13 個(gè)金幣 ,回帖就立即獲得 1 個(gè)金幣,每人有 1 次機(jī)會(huì) | |||
[交流]
哈佛大學(xué)醫(yī)學(xué)院/波士頓兒童醫(yī)院Ye Sun老師課題組誠聘博士后
|
|||
|
Postdoctoral Position at Harvard Medical School Job Title: Postdoctoral Fellow Status: Regular Full Time Benefits Eligible: Yes Laboratory/Department: The laboratory of Dr. Ye Sun is in the Ophthalmology Department at Harvard Medical School and Boston Children's Hospital. The research interests in the Sun Lab focus on the molecular mechanisms during the progression of eye disorders, especially the role of immune-vascular interaction and neuroinflammation in retinal angiogenesis and degeneration in vascular eye diseases. https://immunologyphd.hms.harvard.edu/people/ye-sun Position Description: The NIH-funded postdoctoral position is immediately available and offers the exciting opportunity to learn cutting-edge technologies and be on the forefront of medical research. The position will involve the use of disease mouse models, Cre/loxP system, immunohistochemistry, western blotting, qRT-PCR, cloning, AAV preparation, flow cytometer, two-photon microscopy, confocal microscopy and other living imaging techniques. In addition, there will be many opportunities to collaborate with various labs both within Harvard Medical School and Boston Children's Hospital, and the surrounding hospitals and research institutions. The position provides incredible opportunities to work on a translational disease model in the world renown Longwood Medical Area. Supported by a community of talented clinicians and researchers in the world's largest pediatric research center, the position will help hone research skills, critical and interdisciplinary thinking, and scientific writing. Education: Candidates should have a PhD in immunology, molecular biology, biochemistry, genetics, or biomedical sciences and previous experience with microscopy and image analysis in a biological context, i.e. immunology, neurobiology, developmental biology, molecular and cellular biology, or genetics. Preference will be given to highly motivated and focused applicants with evidence of excellent communication, scientific engagement and published papers in peer-reviewed journals. Application Instructions: Applicants should submit a cover letter detailing their research experiences and interests, a CV, a potential start date, and the full contact information of three references to ye.sun@childrens.harvard.edu 發(fā)自小木蟲IOS客戶端 |
» 搶金幣啦!回帖就可以得到:
+3/192
+1/99
+1/99
+1/80
+2/76
+2/48
+1/36
+1/34
+1/26
+1/22
+1/14
+1/11
+1/8
+1/4
+1/4
+1/3
+1/3
+1/2
+1/1
+1/1
禁蟲 (文學(xué)泰斗)
|
本帖內(nèi)容被屏蔽 |




| 19 | 1/1 | 返回列表 |
| 最具人氣熱帖推薦 [查看全部] | 作者 | 回/看 | 最后發(fā)表 | |
|---|---|---|---|---|
|
[考研]
一志愿天津大學(xué)材料與化工275求調(diào)劑
10+5
|
穿只靴子 2026-03-07 | 20/1000 |
|
|---|---|---|---|---|
|
[考研] 0857環(huán)境調(diào)劑 +5 | 熠熠_11 2026-03-10 | 5/250 |
|
|
[考研] 083000環(huán)境科學(xué)與工程調(diào)劑 +8 | mingmingry 2026-03-09 | 9/450 |
|
|
[考研] 420求調(diào)劑 +3 | 莫向外求11 2026-03-10 | 3/150 |
|
|
[考研] 327求調(diào)劑 +3 | Ffff03 2026-03-10 | 3/150 |
|
|
[考研] 調(diào)劑 +5 | 呵唔哦豁 2026-03-10 | 5/250 |
|
|
[考研] 086000生物與醫(yī)藥319分求調(diào)劑 +4 | Tolkien 2026-03-07 | 8/400 |
|
|
[考研] 311求調(diào)劑 +3 | 牛乳糖的卡卡 2026-03-10 | 3/150 |
|
|
[考研] 328,0703考生求調(diào)劑,一志愿為東北師范大學(xué) +3 | 觀素律 2026-03-09 | 4/200 |
|
|
[考研] A區(qū)一本交叉課題組,低分調(diào)劑,招收機(jī)械電子信息通信等交叉方向 +56 | lisimayy 2026-03-04 | 73/3650 |
|
|
[考研] 復(fù)試調(diào)劑 +6 | 呼呼?~+123456 2026-03-08 | 8/400 |
|
|
[考研] 294 英二數(shù)二物化 求調(diào)劑 +6 | 米飯團(tuán)不好吃 2026-03-09 | 6/300 |
|
|
[考研] 320求調(diào)劑 +4 | 魏zy 2026-03-08 | 4/200 |
|
|
[考研] 求調(diào)劑,數(shù)一英一274分 +4 | 小菲會(huì)努力 2026-03-08 | 4/200 |
|
|
[考研] 297求調(diào)劑 +3 | 胡達(dá)靈 2026-03-05 | 5/250 |
|
|
[考研] 288求調(diào)劑085600材料與化工 +13 | Daunrin 2026-03-07 | 15/750 |
|
|
[考研] 334求調(diào)劑 +8 | Trying] 2026-03-06 | 8/400 |
|
|
[考研] 求調(diào)劑 +4 | 呼呼?~+123456 2026-03-06 | 4/200 |
|
|
[考研] 不限學(xué)校專業(yè)的調(diào)劑同學(xué)看過來 +5 | 啊擺啊擺 2026-03-05 | 9/450 |
|
|
[考研] 316求調(diào)劑 +3 | 林小星發(fā)大財(cái) 2026-03-05 | 5/250 |
|